Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Lymphoma 2Small Cell Lung Carcinoma 1Sarcoma 1Prostatic Neoplasms 1Neoplasms 1Neoplasm, Residual 1Lymphoproliferative Disorders 1Lymphomatoid Granulomatosis 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Leukemia, Hairy Cell 1Leukemia 1Epstein-Barr Virus Infections 1Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 91Carboplatin 79Specimen Handling 76Magnetic Resonance Spectroscopy 64Pemetrexed 60Cisplatin 49durvalumab 44Paclitaxel 38Nivolumab 34atezolizumab 32Radiotherapy 30Radiosurgery 30osimertinib 29Blood Specimen Collection 27Biopsy 26Gemcitabine 24Docetaxel 24Immunoglobulin G 23Standard of Care 22Disulfides 22Etoposide 21Drug Therapy 21Taxes 18Practice Guidelines as Topic 18Radiation 17Educational Status 16130-nm albumin-bound paclitaxel 15X-Rays 14Surveys and Questionnaires 14Bevacizumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × Caves × 1 year × Clear all
NCT02769962 2025-07-28

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
45 enrolled 30 charts
GenitourinaryThoracic

Carcinoma, Transitional Cell, Lung Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡